Literature DB >> 23480362

Multiple antigen peptide containing B and T cell epitopes of F1 antigen of Yersinia pestis showed enhanced Th1 immune response in murine model.

R Ali1, R A Naqvi, S Kumar, A A Bhat, D N Rao.   

Abstract

Yersinia pestis is a facultative bacterium that can survive and proliferate inside host macrophages and cause bubonic, pneumonic and systemic infection. Apart from humoral response, cell-mediated protection plays a major role in combating the disease. Fraction 1 capsular antigen (F1-Ag) of Y. pestis has long been exploited as a vaccine candidate. In this study, F1-multiple antigenic peptide (F1-MAP or MAP)-specific cell-mediated and cytokine responses were studied in murine model. MAP consisting of three B and one T cell epitopes of F1-antigen with one palmitoyl residue was synthesized using Fmoc chemistry. Mice were immunized with different formulations of MAP in poly DL-lactide-co-glycolide (PLGA) microspheres. F1-MAP with CpG oligodeoxynucleotide (CpG-ODN) as an adjuvant showed enhanced in vitro T cell proliferation and Th1 (IL-2, IFN-γ and TNF-α) and Th17 (IL-17A) cytokine secretion. Similar formulation also showed significantly higher numbers of cytokine (IL-2, IFN-γ)-secreting cells. Moreover, F1-MAP with CpG formulation showed significantly high (P < 0.001) percentage of CD4(+) IFN-γ(+) cells as compared to CD8(+) IFN-γ(+) cells, and also more (CD4- IFN-γ)(+) cells secrete perforin and granzyme as compared to (CD8- IFN-γ)(+) showing Th1 response. Thus, the study highlights the importance of Th1 cytokine and existence of CD4(+) and CD8(+) immune response. This study proposes a new perspective for the development of vaccination strategies for Y. pestis that trigger T cell immune response.
© 2013 The Authors. Scandinavian Journal of Immunology © 2013 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23480362     DOI: 10.1111/sji.12042

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  6 in total

1.  Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.

Authors:  William Bowen; Lalit Batra; Amanda R Pulsifer; Esma S Yolcu; Matthew B Lawrenz; Haval Shirwan
Journal:  Vaccine       Date:  2019-08-12       Impact factor: 3.641

Review 2.  The impact of "omic" and imaging technologies on assessing the host immune response to biodefence agents.

Authors:  Julia A Tree; Helen Flick-Smith; Michael J Elmore; Caroline A Rowland
Journal:  J Immunol Res       Date:  2014-09-16       Impact factor: 4.818

3.  Yersinia pestis Antigen F1 but Not LcrV Induced Humoral and Cellular Immune Responses in Humans Immunized with Live Plague Vaccine-Comparison of Immunoinformatic and Immunological Approaches.

Authors:  Valentina A Feodorova; Anna M Lyapina; Maria A Khizhnyakova; Sergey S Zaitsev; Yury V Saltykov; Vladimir L Motin
Journal:  Vaccines (Basel)       Date:  2020-11-19

4.  Development of Yersinia pestis F1 antigen-loaded microspheres vaccine against plague.

Authors:  Shih-shiung Huang; I-Hsun Li; Po-da Hong; Ming-kung Yeh
Journal:  Int J Nanomedicine       Date:  2014-02-07

5.  Detection of Dengue Virus-Specific IgM and IgG Antibodies through Peptide Sequences of Envelope and NS1 Proteins for Serological Identification.

Authors:  Pradeep Kumar Nagar; Deepali Savargaonkar; Anupkumar R Anvikar
Journal:  J Immunol Res       Date:  2020-08-04       Impact factor: 4.818

6.  Innovative IgG Biomarkers Based on Phage Display Microbial Amyloid Mimotope for State and Stage Diagnosis in Alzheimer's Disease.

Authors:  Laura M De Plano; Santina Carnazza; Domenico Franco; Maria Giovanna Rizzo; Sabrina Conoci; Salvatore Petralia; Alessandra Nicoletti; Mario Zappia; Michela Campolo; Emanuela Esposito; Salvatore Cuzzocrea; Salvatore P P Guglielmino
Journal:  ACS Chem Neurosci       Date:  2020-03-24       Impact factor: 4.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.